title: Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.
abstract: BACKGROUND
  Gout prevalence increased in recent years to become one of the most common causes of inflammatory arthritis in most industrialised countries. Comorbidities may affect the disease severity and treatment patterns. We describe the main characteristics of gout patients, gout-related treatment patterns and prevalent comorbidities in a managed care population.
  
  
  METHODS
  From the large US PharMetrics Patient-Centric Database, patients aged 20-89 with at least 2 claims for a diagnosis of gout (ICD9 274.xx) and related prescriptions between January 1, 1996 and December 31, 2008 were included. Gout flares were ascertained during follow-up. Sex-specific multivariable Poisson regression models were used to assess factors associated with number of flares.
  
  
  RESULTS
  177,637 gout patients were included (mean age 55.2 years; men 75.6%). Overall, more than half (58.1%) had any of the considered comorbidities; hypertension (36.1%), dyslipidemia (27.0%) and diabetes (15.1%) being the most common. Nonselective NSAIDs were the most commonly dispensed (in 38.7% of patients). Notably, 39% of patients did not receive any prescription medication for gout. Patients with comorbidities were significantly more likely to receive anti-gout prescriptions. During an acute episode the prescription of NSAIDs and colchicine increased; and 29.9% of patients received allopurinol. The risk of flares was associated with cardiometabolic comorbidities and older age in women (highest at age 60-69), while in men it decreased by age. Women with these conditions were 60% more likely to have flares (incidence rate ratio, IRR 1.60;1.48-1.74), while men were 10% (IRR 1.10; 1.06-1.13) more likely.
  
  
  CONCLUSIONS
  Comorbidities affected gout treatment patterns and the occurrence and frequency of acute attacks. Cardiometabolic comorbidities, common in this patients' population, were associated with an increased risk of flares.
authors: Global Clinical Epidemiology, Novartis Pharma, Basel, Switzerland. paola.primatesta@novartis.com
authors: Paola
authors: P
authors: Primatesta
authors: Estel
authors: E
authors: Plana
authors: Dietrich
authors: D
authors: Rothenbacher
references: Rheumatology (Oxford). 2010 Jan;49(1):105-11
references: 19920095
references: Postgrad Med J. 2005 Sep;81(959):572-9
references: 16143687
references: J Clin Rheumatol. 2006 Apr;12(2):61-5
references: 16601538
references: Ann Rheum Dis. 2009 Aug;68(8):1265-70
references: 18701554
references: Ann Rheum Dis. 2007 Oct;66(10):1269-70
references: 17881662
references: Ann Rheum Dis. 2005 Feb;64(2):267-72
references: 15647434
references: Arthritis Rheum. 2006 Aug;54(8):2688-96
references: 16871533
references: Ann Rheum Dis. 2007 Oct;66(10):1311-5
references: 17504843
references: Lancet. 2010 Jan 23;375(9711):318-28
references: 19692116
references: J Rheumatol. 2008 Mar;35(3):498-501
references: 18260174
references: Curr Opin Rheumatol. 2008 Mar;20(2):198-202
references: 18349751
references: Clin Ther. 2003 Jun;25(6):1593-617
references: 12860487
references: Arthritis Res Ther. 2006;8 Suppl 1:S3
references: 16820042
references: Rheumatology (Oxford). 2007 Aug;46(8):1372-4
references: 17522099
references: Ann Rheum Dis. 2006 Oct;65(10):1301-11
references: 16707533
references: Mayo Clin Proc. 2006 Jul;81(7):925-34
references: 16835972
references: J Rheumatol. 2006 Jan;33(1):104-9
references: 16267879
references: Arch Intern Med. 2008 May 26;168(10):1104-10
references: 18504339